GOSS
HealthcareGossamer Bio, Inc.
$0.44-0.03 (-7.21%)
Prev Close
$0.47
Open
$0.46
High
$0.47
Low
$0.42
Volume
6.65M
Market Cap
$129.0M
P/E
—
Div Yield
—
Over the past 12 months, insider activity at Gossamer Bio, Inc. (GOSS) has been exclusively buying, with 1 insider purchase totaling $50.0K and 0 insider sales totaling $0.00. The most recent insider transaction was by Milligan Sandra (Director), who purchased $50.0K worth of shares on Aug 20, 2025. Gossamer Bio, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $129.0M.
Buys (12M)
1
$50.0K
Sells (12M)
0
$0.00
Net Activity
Net Buyer
$50.0K
Active Insiders
1
last 12 mo
GOSS Price Chart
GOSS Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Aug 20, 2025↗ | Milligan Sandra | Director | Buy | 26,050 | $1.92 | $50.0K | 58,050 |
| Jun 25, 2024↗ | Aranda Richard | Chief Medical Officer | Sell | 1,908 | $0.66 | $1.3K | 196,891 |
| Jun 24, 2024↗ | Hasnain Faheem | President & CEO | Buy | 372,000 | $0.67 | $250.3K | 5,408,070 |
| Jun 20, 2024↗ | Giraudo Bryan | COO/CFO | Buy | 100,000 | $0.59 | $59.1K | 480,010 |
| Jun 20, 2024↗ | Smith Robert Paul JR | Chief Commercial Officer | Buy | 25,000 | $0.60 | $15.1K | 25,000 |
| Mar 28, 2024↗ | Christian Waage | EVP, Tech Ops and Admin | Sell | 6,430 | $1.16 | $7.4K | 585,934 |
| Mar 28, 2024↗ | Giraudo Bryan | COO/CFO | Sell | 6,430 | $1.16 | $7.4K | 92,737 |
| Mar 28, 2024↗ | Hasnain Faheem | President & CEO | Sell | 23,172 | $1.16 | $26.8K | 120,293 |
| Mar 19, 2024↗ | Aranda Richard | Chief Medical Officer | Sell | 4,018 | $1.33 | $5.3K | 198,799 |
| Mar 19, 2024↗ | Peterson Caryn | EVP, Regulatory Affairs | Sell | 4,018 | $1.33 | $5.3K | 49,833 |
| Nov 17, 2023↗ | Milligan Sandra | Director | Buy | 32,000 | $0.79 | $25.2K | 32,000 |
| Nov 14, 2023↗ | Giraudo Bryan | COO/CFO | Buy | 200,000 | $0.56 | $112.9K | 380,010 |
| Jun 26, 2023↗ | Aranda Richard | Chief Medical Officer | Sell | 1,814 | $1.29 | $2.3K | 197,574 |
| Apr 5, 2023↗ | Giraudo Bryan | COO/CFO | Buy | 55,000 | $1.02 | $56.1K | 125,990 |
| Mar 22, 2023↗ | Christian Waage | EVP, Tech Ops and Admin | Buy | 18,500 | $1.20 | $22.1K | 32,388 |
| Mar 22, 2023↗ | Giraudo Bryan | COO/CFO | Buy | 50,000 | $0.97 | $48.4K | 70,990 |
| Mar 22, 2023↗ | Hasnain Faheem | President & CEO | Buy | 878,572 | $1.14 | $1.00M | 4,495,900 |
| Mar 20, 2023↗ | Aranda Richard | Chief Medical Officer | Sell | 7,563 | $1.10 | $8.3K | 199,388 |
| Mar 20, 2023↗ | Carter Laura | Chief Scientific Officer | Sell | 6,029 | $1.10 | $6.6K | 76,263 |
| Mar 20, 2023↗ | Peterson Caryn | EVP, Regulatory Affairs | Sell | 7,564 | $1.10 | $8.3K | 53,851 |
| Oct 25, 2022↗ | Aranda Richard | Chief Medical Officer | Sell | 4,757 | $12.07 | $57.4K | 205,430 |
| Oct 25, 2022↗ | Carter Laura | Chief Scientific Officer | Sell | 4,876 | $12.07 | $58.9K | 82,292 |
| Oct 25, 2022↗ | Peterson Caryn | EVP, Regulatory Affairs | Sell | 4,757 | $12.07 | $57.4K | 61,415 |
| Jul 15, 2022↗ | Carter Laura | Chief Scientific Officer | Buy | 6,934 | $7.21 | $50.0K | 87,168 |
| Jul 15, 2022↗ | Christian Waage | EVP, Tech Ops and Admin | Buy | 6,934 | $7.21 | $50.0K | 13,888 |
| Jul 15, 2022↗ | Giraudo Bryan | COO/CFO | Buy | 13,869 | $7.21 | $100.0K | 20,990 |
| Jul 15, 2022↗ | Hasnain Faheem | President & CEO | Buy | 138,696 | $7.21 | $1000.0K | 3,617,320 |
| Jul 5, 2022↗ | Carter Laura | Chief Scientific Officer | Sell | 8,808 | $8.25 | $72.6K | 80,234 |
| Jun 23, 2022↗ | Aranda Richard | Chief Medical Officer | Sell | 1,778 | $6.88 | $12.2K | 209,897 |
| May 5, 2022↗ | Carter Laura | Chief Scientific Officer | Sell | 1,262 | $7.20 | $9.1K | 89,042 |
| Mar 24, 2022↗ | Christian Waage | EVP, Tech Ops and Admin | Sell | 10,722 | $8.91 | $95.6K | 579,008 |
| Mar 24, 2022↗ | Giraudo Bryan | COO/CFO | Sell | 10,722 | $8.91 | $95.6K | 99,167 |
| Mar 24, 2022↗ | Hasnain Faheem | President & CEO | Sell | 19,035 | $8.91 | $169.7K | 143,465 |
| Mar 17, 2022↗ | Aranda Richard | Chief Medical Officer | Sell | 6,278 | $8.28 | $52.0K | 211,675 |
| Mar 17, 2022↗ | Carter Laura | Chief Scientific Officer | Sell | 5,002 | $8.28 | $41.4K | 90,304 |
| Mar 17, 2022↗ | Peterson Caryn | EVP, Regulatory Affairs | Sell | 6,279 | $8.28 | $52.0K | 66,172 |
| Oct 26, 2021↗ | Aranda Richard | Chief Medical Officer | Sell | 2,377 | $12.25 | $29.1K | 217,432 |
| Oct 26, 2021↗ | Carter Laura | Chief Scientific Officer | Sell | 2,377 | $12.25 | $29.1K | 95,306 |
| Oct 26, 2021↗ | Peterson Caryn | EVP, Regulatory Affairs | Sell | 2,377 | $12.25 | $29.1K | 72,451 |
| Mar 25, 2021↗ | Christian Waage | EVP & General Counsel | Sell | 5,490 | $9.48 | $52.1K | 588,199 |
| Mar 25, 2021↗ | Giraudo Bryan | Chief Financial Officer | Sell | 5,490 | $9.48 | $52.0K | 109,889 |
| Mar 25, 2021↗ | Salter-Cid Luisa | Chief Scientific Officer | Sell | 5,491 | $9.48 | $52.1K | 206,065 |
GOSS Insider Buying Activity
The following table shows recent insider purchases of Gossamer Bio, Inc. (GOSS) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Aug 20, 2025↗ | Milligan Sandra | Director | Buy | 26,050 | $1.92 | $50.0K | 58,050 |
| Jun 24, 2024↗ | Hasnain Faheem | President & CEO | Buy | 372,000 | $0.67 | $250.3K | 5,408,070 |
| Jun 20, 2024↗ | Giraudo Bryan | COO/CFO | Buy | 100,000 | $0.59 | $59.1K | 480,010 |
| Jun 20, 2024↗ | Smith Robert Paul JR | Chief Commercial Officer | Buy | 25,000 | $0.60 | $15.1K | 25,000 |
| Nov 17, 2023↗ | Milligan Sandra | Director | Buy | 32,000 | $0.79 | $25.2K | 32,000 |
| Nov 14, 2023↗ | Giraudo Bryan | COO/CFO | Buy | 200,000 | $0.56 | $112.9K | 380,010 |
| Apr 5, 2023↗ | Giraudo Bryan | COO/CFO | Buy | 55,000 | $1.02 | $56.1K | 125,990 |
| Mar 22, 2023↗ | Christian Waage | EVP, Tech Ops and Admin | Buy | 18,500 | $1.20 | $22.1K | 32,388 |
| Mar 22, 2023↗ | Giraudo Bryan | COO/CFO | Buy | 50,000 | $0.97 | $48.4K | 70,990 |
| Mar 22, 2023↗ | Hasnain Faheem | President & CEO | Buy | 878,572 | $1.14 | $1.00M | 4,495,900 |
| Jul 15, 2022↗ | Carter Laura | Chief Scientific Officer | Buy | 6,934 | $7.21 | $50.0K | 87,168 |
| Jul 15, 2022↗ | Christian Waage | EVP, Tech Ops and Admin | Buy | 6,934 | $7.21 | $50.0K | 13,888 |
| Jul 15, 2022↗ | Giraudo Bryan | COO/CFO | Buy | 13,869 | $7.21 | $100.0K | 20,990 |
| Jul 15, 2022↗ | Hasnain Faheem | President & CEO | Buy | 138,696 | $7.21 | $1000.0K | 3,617,320 |
GOSS Insider Selling Activity
The following table shows recent insider sales of Gossamer Bio, Inc. (GOSS) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jun 25, 2024↗ | Aranda Richard | Chief Medical Officer | Sell | 1,908 | $0.66 | $1.3K | 196,891 |
| Mar 28, 2024↗ | Christian Waage | EVP, Tech Ops and Admin | Sell | 6,430 | $1.16 | $7.4K | 585,934 |
| Mar 28, 2024↗ | Giraudo Bryan | COO/CFO | Sell | 6,430 | $1.16 | $7.4K | 92,737 |
| Mar 28, 2024↗ | Hasnain Faheem | President & CEO | Sell | 23,172 | $1.16 | $26.8K | 120,293 |
| Mar 19, 2024↗ | Aranda Richard | Chief Medical Officer | Sell | 4,018 | $1.33 | $5.3K | 198,799 |
| Mar 19, 2024↗ | Peterson Caryn | EVP, Regulatory Affairs | Sell | 4,018 | $1.33 | $5.3K | 49,833 |
| Jun 26, 2023↗ | Aranda Richard | Chief Medical Officer | Sell | 1,814 | $1.29 | $2.3K | 197,574 |
| Mar 20, 2023↗ | Aranda Richard | Chief Medical Officer | Sell | 7,563 | $1.10 | $8.3K | 199,388 |
| Mar 20, 2023↗ | Carter Laura | Chief Scientific Officer | Sell | 6,029 | $1.10 | $6.6K | 76,263 |
| Mar 20, 2023↗ | Peterson Caryn | EVP, Regulatory Affairs | Sell | 7,564 | $1.10 | $8.3K | 53,851 |
| Oct 25, 2022↗ | Aranda Richard | Chief Medical Officer | Sell | 4,757 | $12.07 | $57.4K | 205,430 |
| Oct 25, 2022↗ | Carter Laura | Chief Scientific Officer | Sell | 4,876 | $12.07 | $58.9K | 82,292 |
| Oct 25, 2022↗ | Peterson Caryn | EVP, Regulatory Affairs | Sell | 4,757 | $12.07 | $57.4K | 61,415 |
| Jul 5, 2022↗ | Carter Laura | Chief Scientific Officer | Sell | 8,808 | $8.25 | $72.6K | 80,234 |
| Jun 23, 2022↗ | Aranda Richard | Chief Medical Officer | Sell | 1,778 | $6.88 | $12.2K | 209,897 |
| May 5, 2022↗ | Carter Laura | Chief Scientific Officer | Sell | 1,262 | $7.20 | $9.1K | 89,042 |
| Mar 24, 2022↗ | Christian Waage | EVP, Tech Ops and Admin | Sell | 10,722 | $8.91 | $95.6K | 579,008 |
| Mar 24, 2022↗ | Giraudo Bryan | COO/CFO | Sell | 10,722 | $8.91 | $95.6K | 99,167 |
| Mar 24, 2022↗ | Hasnain Faheem | President & CEO | Sell | 19,035 | $8.91 | $169.7K | 143,465 |
| Mar 17, 2022↗ | Aranda Richard | Chief Medical Officer | Sell | 6,278 | $8.28 | $52.0K | 211,675 |
| Mar 17, 2022↗ | Carter Laura | Chief Scientific Officer | Sell | 5,002 | $8.28 | $41.4K | 90,304 |
| Mar 17, 2022↗ | Peterson Caryn | EVP, Regulatory Affairs | Sell | 6,279 | $8.28 | $52.0K | 66,172 |
| Oct 26, 2021↗ | Aranda Richard | Chief Medical Officer | Sell | 2,377 | $12.25 | $29.1K | 217,432 |
| Oct 26, 2021↗ | Carter Laura | Chief Scientific Officer | Sell | 2,377 | $12.25 | $29.1K | 95,306 |
| Oct 26, 2021↗ | Peterson Caryn | EVP, Regulatory Affairs | Sell | 2,377 | $12.25 | $29.1K | 72,451 |
| Mar 25, 2021↗ | Christian Waage | EVP & General Counsel | Sell | 5,490 | $9.48 | $52.1K | 588,199 |
| Mar 25, 2021↗ | Giraudo Bryan | Chief Financial Officer | Sell | 5,490 | $9.48 | $52.0K | 109,889 |
| Mar 25, 2021↗ | Salter-Cid Luisa | Chief Scientific Officer | Sell | 5,491 | $9.48 | $52.1K | 206,065 |
GOSS Insiders
Similar Stocks to GOSS
VRTX
Vertex Pharmaceuticals Incorporated
$452.29-2.20%
$121.44B
REGN
Regeneron Pharmaceuticals, Inc.
$745.34-1.66%
$77.57B
ALNY
Alnylam Pharmaceuticals, Inc.
$317.24-0.96%
$42.07B
INSM
Insmed Incorporated
$143.85-0.06%
$30.07B
UTHR
United Therapeutics Corporation
$531.23-1.63%
$23.50B
MRNA
Moderna, Inc.
$52.27-3.15%
$20.76B
ROIV
Roivant Sciences Ltd.
$27.86-1.55%
$20.08B
RPRX
Royalty Pharma plc
$45.94-0.36%
$19.56B